

Supplementary Table S1 Immunotherapy discontinuation criteria

Study (trial identifier)	Immunotherapy discontinuation criteria
Amin 2018 (1) (CheckMate 016)	PD, unacceptable toxicity, consent withdrawal, clinical judgment
Amin 2018 (2) (CheckMate 016)	PD, unacceptable toxicity, consent withdrawal, clinical judgment
Atkins 2018 (NCT02133742)	PD, CR, unacceptable toxicity, consent withdrawal
Choueiri 2020 (JAVELIN Renal 101)	PD, unacceptable toxicity, consent withdrawal, loss to follow-up, death
Dudek 2020 (1) (BTCRC-GU14-003)	PD, unacceptable toxicity, consent withdrawal, death
Dudek 2020 (2) (BTCRC-GU14-003)	PD, unacceptable toxicity, consent withdrawal, death
Hammers (1) 2017 (CheckMate 016)	PD, unacceptable toxicity, consent withdrawal, clinical judgment
Hammers (2) 2017 (CheckMate 016)	PD, unacceptable toxicity, consent withdrawal, clinical judgment
McKay 2020 (OMNIVORE)	PR, CR, PD, unacceptable toxicity, consent withdrawal
Motzer 2020 (CheckMate 025)	PD, unacceptable toxicity, consent withdrawal
Motzer 2020 (CheckMate 214)	PD, unacceptable toxicity, consent withdrawal, end of 2-year treatment (amendment)
Naing 2019 (IVY)	PD, unacceptable toxicity, consent withdrawal, study end
Ornstein 2019 (NCT03126331)	PD, unacceptable toxicity, consent withdrawal
Topalian 2019 (CA209-003)	PD, CR, unacceptable toxicity, consent withdrawal
Vaishampayan 2019 (1) (JAVELIN Solid Tumor)	PD, unacceptable toxicity, consent withdrawal, death
Vaishampayan 2019 (2) (JAVELIN Solid Tumor)	PD, unacceptable toxicity, consent withdrawal, death

CR, complete response; PD, progressive disease; PR, partial response.